Home › Research › Brain tissue and pathology
Plasma eMTBR-tau as a robust biomarker for Alzheimer’s disease tangle pathology up to 10 years before death
Shi R, Zeng X, Farinas MF, Nafash MN, Smirnov DS, Kamboh MI, Snitz BE, Kofler JK et al.. medRxiv, 2026-10-05
Topic: Plasma and spinal-fluid biomarkers
Plain-language summary
Scalable and accessible biomarkers of neurofibrillary tangle pathology are needed for Alzheimer’s disease prognosis, diagnosis and monitoring. Here, we show that a blood-based immunoassay for an endogenously-cleaved “eMTBR-tau” fragment of tau protein is strongly associated with autopsy-diagnosed Alzheimer neuropathologic change (ADNC) and predominantly reflects the burden and anatomical progression of tangle pathology but not amyloid plaque load despite being most elevated in amyloid-positive symptomatic individuals. Plasma eMTBR-tau was significantly more accurate than plasma p-tau217 in classifying Braak staging and ADNC statuses at autopsy. Importantly, neuropathologic classification by plasma eMTBR-tau remained high (AUC=0.91-0.95) even when increasing intervals between blood collection and death up to a decade, while maintaining superior sensitivity and specificity over p-tau217. Higher baseline plasma eMTBR-tau was associated with worse cognition cross-sectionally and longitudinally predicted faster worsening. These results were replicated in a living cohort with in vivo tangle and plaque neuroimaging. Plasma eMTBR-tau concordance with tau neuroimaging was up to 94%, suggesting surrogacy. Together, plasma eMTBR-tau captures biological signatures of Braak staging and ADNC over a prolonged pre-mortem window, highlighting potential for early disease detection, biological staging, prognosis and therapeutic development.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Shi, R., Zeng, X., Farinas, M. F., Nafash, M. N., Smirnov, D. S., Kamboh, M. I., et al. (2026). Plasma eMTBR-tau as a robust biomarker for Alzheimer’s disease tangle pathology up to 10 years before death. medRxiv. https://doi.org/10.64898/2026.09.29.26363951
Vancouver
Shi R, Zeng X, Farinas MF, Nafash MN, Smirnov DS, Kamboh MI, et al. Plasma eMTBR-tau as a robust biomarker for Alzheimer’s disease tangle pathology up to 10 years before death. medRxiv. 2026. doi:10.64898/2026.09.29.26363951.
BibTeX
@article{shi2026-09101ef3,
author = {Shi, R. and Zeng, X. and Farinas, M. F. and Nafash, M. N. and Smirnov, D. S. and Kamboh, M. I. and Snitz, B. E. and Kofler, J. K. and others},
title = {{Plasma eMTBR-tau as a robust biomarker for Alzheimer’s disease tangle pathology up to 10 years before death}},
journal = {medRxiv},
year = {2026},
doi = {10.64898/2026.09.29.26363951},
url = {https://doi.org/10.64898/2026.09.29.26363951}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Here, we show that a blood-based immunoassay for an endogenously-cleaved “eMTBR-tau” fragment of tau protein is strongly associated with autopsy-diagnosed Alzheimer neuropathologic change (ADNC) and predominantly reflects the burden and anatomical progression of tangle pathology but not amyloid plaque load despite being most elevated in amyloid-positive symptomatic individuals.
- Plasma eMTBR-tau was significantly more accurate than plasma p-tau217 in classifying Braak staging and ADNC statuses at autopsy.
- Higher baseline plasma eMTBR-tau was associated with worse cognition cross-sectionally and longitudinally predicted faster worsening.
- These results were replicated in a living cohort with in vivo tangle and plaque neuroimaging.
Study details
- Effect sizeAUC=0.91-0.95
- Evidence strengthModerate
How this study scored 16/100
Preprint — not yet peer-reviewed. It scored 29 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for study design, sample size, studied in people and randomized / blinded because the record does not state it. We have no data on times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 18 of the 62 points we could judge it on, which is 29 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 2 / 10 | Tier 4 — not a peer-reviewed journal (medRxiv) |
| Journal's citation record | 0 / 4 | Not a journal article, so the journal's record does not count |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 4 / 10 | Preprint — not yet peer-reviewed. Hosted on a preprint server. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 18 / 62 | Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 18 of the 62 points we could judge it on is 29 out of 100. |
| Total | 29 / 100 | Capped to 16 because this is not a peer-reviewed article. |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Brain tissue and pathology from nearby years
Also tagged “p-tau217”
693 studies in the library carry the topic tag “p-tau217”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 693 tagged studies.